加拿大乳腺癌实践指南:关于HR+/HER2-转移性乳腺癌患者2025年系统治疗的全国共识建议
Katarzyna J Jerzak1, Aalok Kumar2, Jean-François Boileau3
1Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
Current oncology (Toronto, Ont.)
|February 26, 2026
概括
加拿大新指导方针为管理激素受体阳性 (HR+),HER2阴性转移性乳腺癌提供了基于证据的建议. 这些指导方针侧重于整合精确瘤学和向治疗,以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 临床实践指南 临床实践指南
背景情况:
- 激素受体阳性 (HR+),人体表皮生长因子受体2-阴性 (HER2-) 乳腺癌占乳腺癌病例的显著多数.
- 针对HR+/HER2-转移性乳腺癌的治疗环境最近取得了进展,引入了具有已证明临床益处的新型治疗方法.
研究的目的:
- 为加拿大管理HR+/HER2-转移性乳腺癌制定基于证据的共识建议.
- 提供关于最佳治疗策略,精确瘤整合和治疗顺序的指导.
主要方法:
- 采用了经过修改的Delphi方法,涉及多轮匿名投票.
- 为了最终确定建议,制定了75%的共识门.
- 研究卓越,积极领导力加拿大乳腺癌联盟 (REAL联盟) 制定了建议,该联盟包括瘤学家和患者倡导代表.
主要成果:
- 在加拿大医疗保健系统内,就管理HR+/HER2转移性乳腺癌的最佳实践达成共识.
- 指导方针涉及精确瘤学和向治疗的整合.
- 建议强调治疗的最佳顺序和平衡治疗效益与患者的生活质量.
结论:
- 开发的共识建议为治疗HR+/HER2-转移性乳腺癌的加拿大临床医生提供了关键的指导.
- 这些建议旨在通过结合先进疗法和以患者为中心的考虑来优化患者护理.
相关概念视频
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K


